Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings

Jazz Pharmaceuticals (JAZZ) is set to report first-quarter 2025 earnings on May 6, after market close. The Zacks Consensus Estimate for the quarter’s sales and earnings is pegged at $978.6 million and$4.61 per share, respectively. The company’s earnings estimates for 2025 have risen from $23.12 per share to$23.33 in the past 60 days. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar) Image Source: Zacks Investment ResearchJAZZ’s Earnings Surprise HistoryJazz Pharmaceuticals’ performa ...